NCT05509023Phase 2Active not recruiting

Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

Study sponsor: Q32 Bio Inc. · QTTB

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-12Estimated
Enrollment · participants102Estimated
Source updated2024-10-03Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview